Islet cell failure in type 2 diabetes
Open accessThe DOI matches its Crossref record; 134 of the 134 references it cites were found in a registry or an index; none of the 272 sources its claims cite is checked for support yet.
Abstract
The major focus of this Review is on the mechanisms of islet beta cell failure in the pathogenesis of obesity-associated type 2 diabetes (T2D). As this demise occurs within the context of beta cell compensation for insulin resistance, consideration is also given to the mechanisms involved in the compensation process, including mechanisms for expansion of beta cell mass and for enhanced beta cell performance. The importance of genetic, intrauterine, and environmental factors in the determination of "susceptible" islets and overall risk for T2D is reviewed. The likely mechanisms of beta cell failure are discussed within the two broad categories: those with initiation and those with progression roles.
Overview
CoChat Summary
## TL;DR
This is a 2006 review arguing that type 2 diabetes develops when insulin-resistant islets can no longer sustain compensatory b cell function, leading first to dysfunction and then progressive loss of b cell mass. It emphasizes that “susceptible” islets are shaped by genetic, intrauterine, and environmental factors, and that hyperglycemia accelerates damage through glucotoxic and glucolipotoxic mechanisms.
## Key findings
- In longitudinal studies, insulin levels rise during the normoglycemic and prediabetes phases and then decline when fasting glycemia exceeds the upper normal limit of 5.5 mM, marking b cell failure.
- A longitudinal study in Pima Indians found that b cell dysfunction was the major determinant of progression from normoglycemia to diabetes.
- In autopsy pancreata from 124 subjects, the paper reports a 40% and 63% loss of islet b cell volume in obese subjects with impaired fasting glucose and T2D, respectively, compared with weight-matched controls; lean T2D subjects had a 41% loss versus lean controls.
- The paper reports that the STOP-NIDDM trial showed acarbose treatment of IGT subjects reduced the risk of progression to diabetes by 36%.
## Methods
- Narrative review of mechanistic, animal, human postmortem, genetic, and epidemiologic studies on islet b cell compensation and failure in obesity-associated T2D.
- Synthesizes findings from rodent models (including ZF, ZDF, DBA2, GK, and IUGR models) and human islet/pancreas studies, including a transcript profiling study of 7 normal and 5 T2D human islet samples.
- Main analysis is integrative and conceptual: it organizes evidence into mechanisms that promote compensation and mechanisms with initiation versus progression roles in b cell failure.
## Limitations
- The paper states that the mechanisms of b cell compensation are “not fully understood,” and that the role of several proposed factors remains to be established or warrants further investigation.
- It explicitly notes uncertainty about several mechanisms, including whether nonimmune islet inflammation contributes in vivo, whether IAPP is causal in b cell dysfunction and demise, and whether reduced ARNT expression is an early defect or a consequence.
- Evident from the text: this is a review, not a new experimental study, so its conclusions depend on the quality and consistency of the cited animal and human studies rather than on a single primary dataset.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 1 Not valid · 164 Not checked · 38 Own results and interpretations
In the paper
“Longitudinal studies of subjects that develop T2D show a rise in insulin levels in the normoglycemic and prediabetes phases that keep glycemia near normal despite the insulin resistance ( b cell compensation), followed by a decline when fasting glycemia surpasses the upper limit of normal of 5.5 mM ( b cell failure) (5) (Figure 1).”
What the sources say
- Not checked yetcites [5]
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“With respect to the latter, increases were observed in enzymes and metabolites involved in anaplerosis and the malate-pyruvate and citratepyruvate shuttles of ZF islets (12).”
What the sources say
- Not checked yetcites [12]
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“Inhibition of these pathways by phenylacetic acid, which inhibits PC, markedly impeded GSIS (12).”
What the sources say
- Not checked yetcites [12]
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“Studies of islet b cell compensation within models that maintain normoglycemia show upregulation of glucose metabolism pathways (12, 13, 31).”
What the sources say
- Not checked yetcites [12]
- Not checked yetcites [13]
- Not checked yetcites [31]
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“A recent study in Zucker fatty (ZF) rats has provided strong support for PKB activation in the b cell growth response to insulin resistance in this normoglycemic model (11).”
What the sources say
- Not checked yetcites [11]
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
116 more claims
Create a free account to see all 203 claims and to verify the 272 references still open.
- It may state two separate claims as one. 71
- Probably not a substantial claim. 13
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Importantly, several of these studies have demonstrated that fatty acids do not induce beta-cell dysfunction in the absence of elevated glucose, highlighting that fatty acids and glucose are not cytotoxic independently.168,169”
From A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives (2021) · cites this paper as [169]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Notably, impairment of insulin secretion in the presence of an intact β-cell mass also occurs in the early stages of human age-related diabetes123.”
From The telomere syndromes (2012) · cites this paper as [123]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Minor deficiencies in the β-cell machinery may only be exposed in times of metabolic stress, such as pregnancy [75].”
From The Pathophysiology of Gestational Diabetes Mellitus (2018) · cites this paper as [75]
Experimental — accuracy not yet measured
Citations
Cites
Mootha, V. K., Lindgren, C. M., Eriksson, K.-F., Subramanian, A., Sihag, S., Lehar, J., Puigserver, P., Carlsson, E., Ridderstråle, M., Laurila, E., et al. (2003) · Nature Genetics · doi:10.1038/ng1180 · Cited by 10,197
Global and societal implications of the diabetes epidemic
Zimmet, P., Alberti, K. G. M. M., & Shaw, J. (2001) · Nature · doi:10.1038/414782a · Cited by 5,883
β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes
Butler, A. E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R. A., & Butler, P. C. (2003) · Diabetes · doi:10.2337/diabetes.52.1.102 · Cited by 4,011
Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial
Chiasson, J.-L., Josse, R. G., Gomis, R., Hanefeld, M., Karasik, A., & Laakso, M. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08905-5 · Cited by 2,543
Barker, D. J. P., Hales, C. N., Fall, C. H. D., Osmond, C., Phipps, K., & Clark, P. M. S. (1993) · Diabetologia · doi:10.1007/bf00399095 · Cited by 2,468
Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes
Grant, S. F. A., Thorleifsson, G., Reynisdottir, I., Benediktsson, R., Manolescu, A., Sainz, J., Helgason, A., Stefansson, H., Emilsson, V., Helgadottir, A., et al. (2006) · Nature Genetics · doi:10.1038/ng1732 · Cited by 2,287
The biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210
Mitochondrial dysfunction and type 2 diabetes
Lowell, B. B., & Shulman, G. I. (2005) · Science · doi:10.1126/science.1104343 · Cited by 2,070
Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase
Minokoshi, Y., Kim, Y.-B., Peroni, O. D., Fryer, L. G. D., Müller, C., Carling, D., & Kahn, B. B. (2002) · Nature · doi:10.1038/415339a · Cited by 2,053
Weyer, C., Bogardus, C., Mott, D. M., & Pratley, R. E. (1999) · Journal of Clinical Investigation · doi:10.1172/jci7231 · Cited by 1,940
Cited by
Items 601–700 of 1,002
Zheng, S., Zhou, H., Tingting, H., Li, Y., Zhang, Y., Liu, W., & Hu, Y. (2015) · BMC Endocrine Disorders · doi:10.1186/s12902-015-0018-1 · Cited by 42
Kim, S. Y., Lee, J.-H., Merrins, M. J., Gavrilova, O., Bisteau, X., Kaldis, P., Satin, L. S., & Rane, S. G. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.754077 · Cited by 40
“Diabetes is strongly associated with a failure of pancreatic islet -cells, although the mechanisms of -cell failure remain unclear (1, 2).”
BackgroundThe Role of CD36 in Type 2 Diabetes Mellitus: β-Cell Dysfunction and Beyond
Moon, J. S., Karunakaran, U., Elumalai, S., Chung, S. M., & Won, K. C. (2020) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2020.0053 · Cited by 47
Circ-Tulp4 promotes β-cell adaptation to lipotoxicity by regulating soat1 expression
Wu, L., Xiong, L., Li, J., Peng, Z., Zhang, L., Shi, P., Gong, Y., & Xiao, H. (2020) · Journal of Molecular Endocrinology · doi:10.1530/jme-20-0079 · Cited by 40
“In the prediabetic condition, β cells accelerate their proliferation rates to compensate for the β -cell loss caused by apoptosis (Prentki & Nolan 2006, Montanya & Téllez 2009).”
Glycerate from intestinal fructose metabolism induces islet cell damage and glucose intolerance
Wu, Y., Wong, C. W., Chiles, E. N., Mellinger, A. L., Bae, H., Jung, S., Peterson, T., Wang, J., Negrete, M., Huang, Q., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.05.007 · Cited by 45
Andrikopoulos, S. (2009) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2009.09.031 · Cited by 43
Watanabe, Y., Nakayama, K., Taniuchi, N., Horai, Y., Kuriyama, C., Ueta, K., Arakawa, K., Senbonmatsu, T., & Shiotani, M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0116851 · Cited by 39
“As a consequence, pancreatic β-cells respond by increasing insulin secretion to maintain normoglycemia [26].”
BackgroundWang, T., Zhang, R., Ma, X., Wang, S., He, Z., Huang, Y., Xu, B., Li, Y., Zhang, H., Jiang, F., et al. (2018) · Obesity · doi:10.1002/oby.22167 · Cited by 45
“The present evidence presents mixed findings regarding the impact of a predisposition to BMI on b-cell function (12-14).”
BackgroundSantos, L. R. B., & Fleming, I. (2019) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2019.106407 · Cited by 47
mTORC1 pathway mediates beta cell compensatory proliferation in 60 % partial-pancreatectomy mice
Li, W., Zhang, H., Nie, A., Ni, Q., Li, F., Ning, G., Li, X., Gu, Y., & Wang, Q. (2016) · Endocrine · doi:10.1007/s12020-016-0861-5 · Cited by 37
“Studies in rodents have shown that beta cell mass expands as insulin secretory load increases, as in pregnancy and obesity, and subsequently declines till diabetes develops [39, 41].”
BackgroundDeficiency of PRKD2 triggers hyperinsulinemia and metabolic disorders
Xiao, Y., Wang, C., Chen, J., Lu, F., Wang, J., Hou, N., Hu, X., Zeng, F., Ma, D., Sun, X., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04352-z · Cited by 40
Oberhauser, L., & Maechler, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010324 · Cited by 44
Tsuyama, T., Sato, Y., Yoshizawa, T., Matsuoka, T., & Yamagata, K. (2023) · EMBO Reports · doi:10.15252/embr.202256227 · Cited by 44
“…has deleterious effects on b -cell function through various mechanisms, including oxidative stress, endoplasmic reticulum (ER) stress, and inflammation and contributes to the development and progression of type 2 diabetes (Prentki & Nolan, 2006; Kahn et al , 2014; Hudish et al , 2019).”
High Fat Programming of β-Cell Failure
Cerf, M. E. (2010) · Advances in experimental medicine and biology · doi:10.1007/978-90-481-3271-3_5 · Cited by 44
Modi, H., Cornu, M., & Thorens, B. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.587733 · Cited by 42
“Preserving glucose homeostasis over a lifetime requires that beta cells adapt their number and secretion capacity in response to different diets as well as to variations in insulin sensitivity of peripheral tissues that occur in obesity, pregnancy, and aging (1).”
BackgroundStimulating β-Cell Regeneration by Combining a GPR119 Agonist with a DPP-IV Inhibitor
Ansarullah, M., Lu, Y., Holstein, M., Brittany, D., Rabinovitch, A., & Guo, Z. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053345 · Cited by 42
The Road From Obesity to Type 2 Diabetes
Ioannidis, I. (2008) · Angiology · doi:10.1177/0003319708318583 · Cited by 40
Suantawee, T., Elazab, S. T., Hsu, W. H., Yao, S., Cheng, H., & Adisakwattana, S. (2017) · Nutrients · doi:10.3390/nu9080814 · Cited by 39
Vong, C. T., Tseng, H. H. L., Kwan, Y. W., Lee, S. M., & Hoi, M. P. M. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.12.126 · Cited by 40
Omori, K., Nakamura, A., Miyoshi, H., Takahashi, K., Kitao, N., Nomoto, H., Kameda, H., Cho, K. Y., Takagi, R., Hatanaka, K. C., et al. (2019) · Metabolism · doi:10.1016/j.metabol.2019.06.006 · Cited by 42
PRMT1 Is Required for the Maintenance of Mature β-Cell Identity
Kim, H., Yoon, B.-H., Oh, C.-M., Lee, J., Lee, K., Song, H., Kim, E., Yi, K., Kim, M., Kim, H., et al. (2019) · Diabetes · doi:10.2337/db19-0685 · Cited by 38
Modeling different types of diabetes using human pluripotent stem cells
Abdelalim, E. M. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03710-9 · Cited by 38
Garg, S. K. (2010) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2009.0127 · Cited by 38
Pioglitazone Acutely Reduces Energy Metabolism and Insulin Secretion in Rats
Lamontagne, J., Jalbert-Arsenault, É., Pépin, É., Peyot, M., Ruderman, N. B., Nolan, C. J., Joly, E. C., Madiraju, S. R. M., Poitout, V., & Prentki, M. (2013) · Diabetes · doi:10.2337/db12-0428 · Cited by 42
Self-citationSystemic Effects of White Adipose Tissue Dysregulation and Obesity‐Related Inflammation
Guri, A. J., & Bassaganya-Riera, J. (2011) · Obesity · doi:10.1038/oby.2010.230 · Cited by 43
Tata, V. D. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15057787 · Cited by 45
Chooi, Y. C., Ding, C., Chan, Z., Choo, J., Sadananthan, S. A., Michael, N., Lee, Y., Velan, S. S., & Magkos, F. (2018) · Obesity · doi:10.1002/oby.22185 · Cited by 37
Feng, M., Lv, H., Xu, X., Wang, J., Lyu, W., & Fu, S. (2019) · Medicine · doi:10.1097/md.0000000000016575 · Cited by 45
Bronczek, G. A., Soares, G. M., de Barros, J. F., Vettorazzi, J. F., Kurauti, M. A., Marconato-Júnior, E., Zangerolamo, L., Marmentini, C., Boschero, A. C., & Costa-Júnior, J. M. (2021) · Scientific Reports · doi:10.1038/s41598-021-88105-x · Cited by 42
Thévenod, F. (2008) · Frontiers in diabetes · doi:10.1159/000152019 · Cited by 76
Glynn, E. J., Thompson, B. M., Vadrevu, S., Lu, S., Kennedy, R. T., Ha, J., Sherman, A., & Satin, L. S. (2015) · Endocrinology · doi:10.1210/en.2015-1563 · Cited by 43
Han, D., Moon, S., Kim, H., Choi, S., Lee, S., Park, K. S., Jun, H., KANG, Y. Y., & Kim, Y. (2010) · Journal of Proteome Research · doi:10.1021/pr100759a · Cited by 43
Dalbøge, L. S., Almholt, D. L. C., Neerup, T. S. R., Vrang, N., Jelsing, J., & Fosgerau, K. (2014) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.215293 · Cited by 35
“Glucolipotoxicity is believed to contribute to the age-dependent decrease in b-cell mass, whereas treatment with liraglutide and the accompanying improvement in glycemic control has been suggested to postpone the age-dependent decline in b-cell mass but not prevent it (Sturis et al., 2003; Prentki and Nolan, 2006; Vra…”
BackgroundImpaired fasting glucose is associated with increased regional cerebral amyloid
Morris, J. K., Vidoni, E. D., Wilkins, H. M., Archer, A. E., Burns, N. C., Karcher, R. T., Graves, R. S., Swerdlow, R. H., Thyfault, J. P., & Burns, J. M. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.04.017 · Cited by 36
Oh, Y. S., Seo, E., Lee, Y.-S., Cho, S. C., Jung, H. S., Park, S. C., & Jun, H. (2016) · PLoS ONE · doi:10.1371/journal.pone.0159689 · Cited by 38
“However, when beta cells fail and can no longer compensate, type 2 diabetes develops [4].”
BackgroundTakahashi, K., Nakamura, A., Miyoshi, H., Nomoto, H., Kitao, N., Omori, K., Yamamoto, K., Cho, K. Y., Terauchi, Y., & Atsumi, T. (2018) · Scientific Reports · doi:10.1038/s41598-018-25126-z · Cited by 36
Saponaro, C., Gmyr, V., Thévenet, J., Moerman, E., Delalleau, N., Pasquetti, G., Coddeville, A., Quenon, A., Daoudi, M., Hubert, T., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.07.009 · Cited by 36
Wang, J., Lv, X., Xu, J., Liu, X., Du, T., Sun, G., Chen, J., Shen, X., Wang, J., & Hu, L. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111976 · Cited by 36
Zhang, Y., Zhang, Y., Halemahebai, G., Tian, L., Dong, H., & Aisker, G. (2020) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2020.113628 · Cited by 37
NADPH Oxidase (NOX) Targeting in Diabetes: A Special Emphasis on Pancreatic β-Cell Dysfunction
Elumalai, S., Karunakaran, U., Moon, J. S., & Won, K. C. (2021) · Cells · doi:10.3390/cells10071573 · Cited by 41
Khetan, S., Kales, S., Kursawe, R., Jillette, A., Ulirsch, J. C., Reilly, S. K., Ucar, D., Tewhey, R., & Stitzel, M. L. (2021) · Nature Communications · doi:10.1038/s41467-021-25514-6 · Cited by 41
The GTPase Rab37 Participates in the Control of Insulin Exocytosis
Ljubicic, S., Bezzi, P., Brajkovic, S., Nesca, V., Guay, C., Ohbayashi, N., Fukuda, M., Abderrhamani, A., & Regazzi, R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0068255 · Cited by 40
“These conditions have been reported to cause b-cell dysfunction [32,33] and are believed to mimic physiopathological conditions that favor the development of diabetes.”
BackgroundCarpentier, A. C., Bourbonnais, A., Frisch, F., Giacca, A., & Lewis, G. F. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1932 · Cited by 44
The Tellurium compound, AS101, increases SIRT1 level and activity and prevents type 2 diabetes
Halperin-Sheinfeld, M., Gertler, A. A., Okun, E., Sredni, B., & Cohen, H. Y. (2012) · Aging · doi:10.18632/aging.100468 · Cited by 36
Clock Gene Dysregulation Induced by Chronic ER Stress Disrupts β-cell Function
Ohta, Y., Taguchi, A., Matsumura, T., Nakabayashi, H., Akiyama, M., Yamamoto, K., Fujimoto, R., Suetomi, R., Yanai, A., Shinoda, K., et al. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.03.040 · Cited by 39
“In addition, recent studies have suggested that glucotoxicity and lipotoxicity induce ER stress responses resulting in β-cell failure (Pretty and Nolan, 2006; Bachar et al., 2009).”
BackgroundTo boldly go—or to go too boldly? The accelerator hypothesis revisited
Gale, E. A. M. (2007) · Diabetologia · doi:10.1007/s00125-007-0726-9 · Cited by 39
Kondegowda, N. G., Mozar, A., Chin, C., Otero, P. A., García-Ocaña, A., & Vasavada, R. C. (2012) · Diabetologia · doi:10.1007/s00125-012-2501-9 · Cited by 37
Schmidt, S. F., Madsen, J. G. S., Frafjord, K. Ø., Poulsen, L. L. C., Salö, S., Boergesen, M., Loft, A., Larsen, B. D., Madsen, M. S., Holst, J. J., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.07.063 · Cited by 39
John, A. N., & Jiang, F. (2017) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2017.12.002 · Cited by 44
Chittezhath, M., Gunaseelan, D., Zheng, X., Hasan, R., Tay, V. S. Y., Lim, S. T., Wang, X., Berggren, P., Bornstein, S. R., Boehm, B. O., et al. (2019) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00248.2019 · Cited by 41
Yang, Y., Kim, J., Park, H., Lee, E., & Yoon, K. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13202 · Cited by 41
Type 2 diabetes – unmet need, unresolved pathogenesis, mTORC1-centric paradigm
Bar‐Tana, J. (2020) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-020-09545-w · Cited by 44
Hypothalamic Neuropeptide 26RFa Acts as an Incretin to Regulate Glucose Homeostasis
Prévost, G., Jeandel, L., Arabo, A., Coëffier, M., Ouahli, M. E., Picot, M., Alexandre, D., Gobet, F., Leprince, J., Berrahmoune, H., et al. (2015) · Diabetes · doi:10.2337/db14-1864 · Cited by 38
FGF1 Mediates Overnutrition-Induced Compensatory β-Cell Differentiation
Li, M., Page-McCaw, P., & Chen, W. (2015) · Diabetes · doi:10.2337/db15-0085 · Cited by 42
Brelje, T. C., Bhagroo, N. V., Stout, L. E., & Sorenson, R. L. (2008) · Journal of Endocrinology · doi:10.1677/joe-07-0657 · Cited by 41
Zhou, T., Quan, L., Chen, L., Du, T., Sun, K., Zhang, J. C., Yu, L., Li, Y., Wan, P., Chen, L. L., et al. (2016) · Cell Death and Disease · doi:10.1038/cddis.2016.119 · Cited by 36
“insulin hypersecretion likely leads to a progressive decline in islet β-cell function.(2) Therefore, an ideal strategy for T2DM treatment is to improve pancreatic β-cell function.”
BackgroundNeuronal glucose sensing mechanisms and circuits in the control of insulin and glucagon secretion
Thorens, B. (2024) · Physiological Reviews · doi:10.1152/physrev.00038.2023 · Cited by 40
“…b -cells and a -cells, which ensures not only the ef fi cient minute-to-minute control of insulin and glucagon secretion in response to glucose variations but also a compensatory change in their total number to adapt to the sensitivity of target tissues to the action of insulin or glucagon (4 – 6).”
BackgroundPathogenesis of Feline Diabetes
Rand, J. S. (2013) · Veterinary Clinics of North America Small Animal Practice · doi:10.1016/j.cvsm.2013.01.003 · Cited by 35
Verma, M. K., Sadasivuni, M. K., Yateesh, A. N., Neelima, K., Mrudula, S., Reddy, M., Smitha, R., Biswas, S., Chandravanshi, B., Pallavi, P. M., et al. (2014) · BMC Cell Biology · doi:10.1186/1471-2121-15-24 · Cited by 41
“Background Reduction in absolute β-cell mass and/or function is linked to type-1 and type-2 diabetes mellitus [1-3].”
BackgroundNagare, T., Sakaue, H., Matsumoto, M., Yongheng, C., Inagaki, K., Sakai, M., Takashima, Y., Nakamura, K., Mori, T., Okada, Y., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.242651 · Cited by 34
Ma, F., Wei, Z., Shi, C., Gan, Y. X., Lu, J., Frank, S. J., Balducci, J., & Huang, Y. (2011) · Molecular Endocrinology · doi:10.1210/me.2011-1052 · Cited by 38
Falcão, V. T. F. L., Maschio, D. A., de Fontes, C. C., de Oliveira, R. B., Santos-Silva, J. C., Almeida, A. C. S., Vanzela, E. C., Cartaxo, M. T., Carvalho, C. P. D. F., & Collares‐Buzato, C. B. (2016) · Histochemistry and Cell Biology · doi:10.1007/s00418-016-1428-5 · Cited by 43
“1 3 tissues in the HFd-treated mice (Kahn et al. 2006; Oliveira et al. 2015; Prentki and Nolan 2006).”
BackgroundGlucose and fatty acids synergistically and reversibly promote beta cell proliferation in rats
Moullé, V. S., Vivot, K., Tremblay, C. C., Zarrouki, B., Ghislain, J. J., & Poitout, V. (2017) · Diabetologia · doi:10.1007/s00125-016-4197-8 · Cited by 39
“Introduction The pancreatic beta cell has a remarkable capacity to adjust to a changingmetabolic environment by increasing its functional mass [1, 2].”
Qarni, A. A. A., Joatar, F. E., Das, N. S., Awad, M., Eltayeb, M., Al-Zubair, A. G., Ali, M. E., Masaud, A. A., Shire, A. M., Gumaa, K. A., et al. (2017) · Endocrinology and Metabolism · doi:10.3803/enm.2017.32.2.230 · Cited by 39
A 2A adenosine receptors control pancreatic dysfunction in high‐fat‐diet‐induced obesity
Csóka, B., Törő, G., Vindeirinho, J., Varga, Z. V., Koscsó, B., Németh, Z. H., Kókai, E., Antonioli, L., Suleiman, M., Marchetti, P., et al. (2017) · The FASEB Journal · doi:10.1096/fj.201700398r · Cited by 38
“Later the progress of T2D,b-cell mass and function decrease, which results in an impairment of glucose-stimulated insulin secretion (GSIS) (2, 4).”
BackgroundInfluentialClerodendrum volubile: Phenolics and Applications to Health
Erukainure, O. L., Sanni, O., & Islam, M. S. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-813006-3.00006-4 · Cited by 36
Metabolic stress activates an ERK/hnRNPK/DDX3X pathway in pancreatic β cells
Good, A. L., Haemmerle, M. W., Oguh, A. U., Doliba, N. M., & Stoffers, D. A. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.05.009 · Cited by 36
Feline comorbidities: Pathophysiology and management of the obese diabetic cat
Clark, M., & Hoenig, M. E. (2021) · Journal of Feline Medicine and Surgery · doi:10.1177/1098612x211021540 · Cited by 62
Rennie, C., Fernandez, R. S., Donnelly, S., & McGrath, K. C. Y. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.728396 · Cited by 45
No Time to Die—How Islets Meet Their Demise in Transplantation
Kale, A., & Rogers, N. M. (2023) · Cells · doi:10.3390/cells12050796 · Cited by 42
“This is typically followed by a second phase of cellular loss, where an inexorable decline in β-cell function can be mediated by allo- and auto-immune destruction, as well as by non-immunological functional impairment and destruction that resembles the failure of islets in T2DM (inflammatory, ER amyloid and metabolic…”
BackgroundSH2B1 in β-Cells Regulates Glucose Metabolism by Promoting β-Cell Survival and Islet Expansion
Chen, Z., Morris, D. L., Jiang, L., Liu, Y., & Rui, L. (2013) · Diabetes · doi:10.2337/db13-0666 · Cited by 35
The Role of Gut Microbiota in High-Fat-Diet-Induced Diabetes: Lessons from Animal Models and Humans
Qi, Y., & Wang, X. (2023) · Nutrients · doi:10.3390/nu15040922 · Cited by 38
“In pre-diabetes, blood glucose can still be maintained at normal levels due to the compensatory response of the beta cells [62].”
BackgroundPlaisance, V., Rolland, L., Gmyr, V., Annicotte, J., Kerr-Conte, J. A., Pattou, F. N., & Abderrahmani, A. (2014) · Journal of Diabetes Research · doi:10.1155/2014/195739 · Cited by 35
Dalle, S., Ravier, M. A., & Bertrand, G. (2010) · Cellular Signalling · doi:10.1016/j.cellsig.2010.09.014 · Cited by 39
Early and Aggressive Initiation of Insulin Therapy for Type 2 Diabetes: What Is the Evidence?
Niswender, K. D. (2009) · Clinical Diabetes · doi:10.2337/diaclin.27.2.60 · Cited by 37
Maschio, D. A., de Oliveira, R. B., dos Santos, M. R., Carvalho, C. P. D. F., Barbosa, H. C. L., & Collares‐Buzato, C. B. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.08.146 · Cited by 36
The pancreas: Bandmaster of glucose homeostasis
Jouvet, N., & Estall, J. L. (2017) · Experimental Cell Research · doi:10.1016/j.yexcr.2017.03.050 · Cited by 49
“It is believed that together, these insults ultimately lead to β-cell failure and cell death [31], triggering dependence on exogenous insulin for maintenance of blood glucose levels (full blown diabetes) [32].”
BackgroundNutrient regulation of pancreatic β-cell proliferation
Moullé, V. S., Ghislain, J. J., & Poitout, V. (2017) · Biochimie · doi:10.1016/j.biochi.2017.09.017 · Cited by 35
The vagus neurometabolic interface and clinical disease
Battinelli, E., Valdés‐Ferrer, S. I., & Steinberg, B. E. (2018) · International Journal of Obesity · doi:10.1038/s41366-018-0086-1 · Cited by 36
Basmaeil, Y. S., Subayyil, A. M. A., Khatlani, T., Bahattab, E., Al-Alwan, M. M., Abomaray, F., Kalionis, B., Alshabibi, M. A., Alaskar, A. S., & Abumaree, M. (2018) · Stem Cell Research & Therapy · doi:10.1186/s13287-018-0984-0 · Cited by 33
The orphan nuclear receptor Nor1/Nr4a3 is a negative regulator of β-cell mass
Close, A.-F., Dadheech, N., Villela, B. S., Rouillard, C., & Buteau, J. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.005135 · Cited by 33
Fiorentino, T. V., Succurro, E., Marini, M. A., Pedace, E., Andreozzi, F., Perticone, M., Sciacqua, A., Perticone, F., & Sesti, G. (2020) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3289 · Cited by 34
Sheng, J., Wang, L., Tang, P. M., Wang, H., Li, J., Xu, B., Xue, V. W., Tan, R., Jin, N., Chan, T., et al. (2021) · Theranostics · doi:10.7150/thno.51857 · Cited by 34
“Indeed, deterioration of beta cell development and function is commonly observed in type 2 diabetes patients and experimental diabetic models [3, 5].”
BackgroundGlucokinase activation or inactivation: Which will lead to the treatment of type 2 diabetes?
Nakamura, A., Omori, K., & Terauchi, Y. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14459 · Cited by 39
Shah, N. Z., Abdalla, M. A., Deshmukh, H., & Sathyapalan, T. (2021) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188211042145 · Cited by 44
Cen, H. H., Hussein, B., Botezelli, J. D., Wang, S., Zhang, J. A., Noursadeghi, N., Jessen, N., Rodrigues, B., Timmons, J. A., & Johnson, J. D. (2021) · The FASEB Journal · doi:10.1096/fj.202100497rr · Cited by 48
Wu, S., Wu, H., Wang, Y., Chang, C., Shan, Y.-S., Wu, S., Chiu, Y., Hsu, C., Juan, H., Lan, K.-Y., et al. (2022) · Autophagy · doi:10.1080/15548627.2022.2123098 · Cited by 38
“However, both dysregulation of insulin secretion and insulin resistance are characteristic features in the HFD-induced obese mouse model [70,74].”
BackgroundGÜLEN, M. İ., Bağla, A. G., Yavuz, Ö., & Hismiogullari, A. (2015) · Biotechnic & Histochemistry · doi:10.3109/10520295.2015.1021380 · Cited by 35
Mathijs, I., Cunha, D. A., Himpe, E., Ladrière, L., Chellan, N., Roux, C. R., Joubert, E., Muller, C. J. F., Cnop, M., Louw, J., et al. (2014) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201400211 · Cited by 39
The Apoptosis Inhibitor ARC Alleviates the ER Stress Response to Promote β-Cell Survival
McKimpson, W. M., Weinberger, J. F., Czerski, L., Zheng, M., Crow, M. T., Pessin, J. E., Chua, S. C., & Kitsis, R. N. (2012) · Diabetes · doi:10.2337/db12-0504 · Cited by 33
Type 2 Diabetes Mellitus and Glucagon Like Peptide-1 Receptor Signalling
Aiysha Thompson, K. (2013) · Clinical & Experimental Pharmacology · doi:10.4172/2161-1459.1000138 · Cited by 33
Kalwat, M. A., Huang, Z., Wichaidit, C., McGlynn, K., Earnest, S. A., Savoia, C., Dioum, E. M., Schneider, J. W., Hutchison, M. R., & Cobb, M. H. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.5b00993 · Cited by 33
Ma, X., Guan, Y., & Hua, X. (2014) · Journal of Diabetes · doi:10.1111/1753-0407.12161 · Cited by 39
“In addition to reduced secretory competence, a deficit of β-cell mass results in failure to produce a sufficient amount of insulin for maintaining normoglycemia in patients with either type 1 or type 2 diabetes (T1D and T2D, respectively).(63,70,71) As such, enhancing β-cell proliferation and regeneration has become a…”
BackgroundInvestigational anti-hyperglycemic agents: the future of type 2 diabetes therapy?
Majumdar, S. K., & Inzucchi, S. E. (2013) · Endocrine · doi:10.1007/s12020-013-9884-3 · Cited by 40
Insulin is a kinetic but not a thermodynamic inhibitor of amylin aggregation
Cui, W., Ma, J., Lei, P., Wu, W., Yu, Y., Yu, X., Tong, A., Zhao, Y., & Li, Y. (2009) · FEBS Journal · doi:10.1111/j.1742-4658.2009.07061.x · Cited by 38
Dai, Y.-L., Huang, S., & Leng, Y. (2015) · International Journal of Biological Sciences · doi:10.7150/ijbs.12108 · Cited by 35
“As a consequence, superfluous fatty acids incorporate into lipids such as triacylglycerol (TG), ceramide, diacylglycerol and other metabolic intermediates, most of which are detrimental to β-cells [12, 14-16].”
BackgroundEffects of metformin on compensatory pancreatic β-cell hyperplasia in mice fed a high-fat diet
Tajima, K., Shirakawa, J., Okuyama, T., Kyohara, M., Yamazaki, S., Togashi, Y., & Terauchi, Y. (2017) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00447.2016 · Cited by 32
Feedback regulation of insulin secretion by extended synaptotagmin‐1
Xie, B., Nguyen, P. M., & Idevall‐Hagren, O. (2018) · The FASEB Journal · doi:10.1096/fj.201801878r · Cited by 34
The autonomic nervous system regulates pancreatic β-cell proliferation in adult male rats
Moullé, V. S., Tremblay, C. C., Castell, A., Vivot, K., Éthier, M., Fergusson, G., Alquier, T., Ghislain, J. J., & Poitout, V. (2019) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00385.2018 · Cited by 39
Tian, M., Reichetzeder, C., Li, J., & Hocher, B. (2019) · Journal of Hypertension · doi:10.1097/hjh.0000000000002156 · Cited by 36
Metadata
- Authors
- Prentki, M.
- Affiliations
- Centre Hospitalier de l’Université de Montréal (CA)
- Corresponding author
- Prentki, M.
- ORCID
- Prentki, M.
- Venue
- Journal of Clinical Investigation
- Published
- 2006-07-03
- Volume
- 116
- Issue
- 7
- Pages
- 1802-1812
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC1483155
- OpenAlex
- W1598254642
- Cited by
- 1,690
- References
- 132
- Citations by year
- 2026: 52 · 2025: 52 · 2024: 46 · 2023: 54 · 2022: 68 · 2021: 95 · 2020: 95 · 2019: 111 · 2018: 90 · 2017: 109 · 2016: 112 · 2015: 107 · 2014: 131 · 2013: 97 · 2012: 98
- FWCI
- 13.11
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- ANU Open Research (Australian National University) (submittedVersion)
- Funders
- ACT Government
- National Institutes of Health
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK063356, DK63356)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- beta-cell failure, type 2 diabetes, obesity, beta-cell compensation, beta-cell mass expansion, insulin resistance, genetic susceptibility, intrauterine factors, environmental risk factors, beta-cell dysfunction
- MeSH terms
- Animals, Diabetes Mellitus, Type 2, Humans, Insulin Resistance, Disease Progression, Genetic Predisposition to Disease, Insulin-Secreting Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.